Development of a Dog Microdialysis Model for Determining Synovial Fluid Pharmacokinetics of Anti-arthritis Compounds Exemplified by Methotrexate

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2003 May 13

PMID 12739768

Citations 3

Authors

Mingxin Qian

Wanda West

Jing-Tao Wu

Bing Lu

David D Christ

Affiliations

Soon will be listed here.

Abstract

Purpose: The purpose of this study was to develop and validate an animal model of drug disposition in synovial fluid (SF) by comparing microdialysis with arthrocentesis using the anti-arthritic drug methotrexate (MTX).

Methods: Microdialysis probes were calibrated in vitro with the no net flux method using dog synovial fluid. The probes were implanted surgically into the stifle joint space of four dogs and were dialyzed overnight using a portable microinfusion pump. The membrane integrity of the probes was monitored by retrodialysis using an internal standard. After an intravenous bolus of 2.5 mg/kg of MTX, unbound concentrations in synovial fluid, as well as total plasma concentrations, were measured by liquid chromatography tandam mass spectrometer (LC/MS/MS) in samples collected from 0 to 48 h postdose.

Results: The probe membrane remained intact at least 48 h after implantation. The mean probe recovery and unbound fraction of MTX in SF were 46.8% and 44.8%, respectively. The unbound fraction of MTX was 44% in synovial fluid. MTX penetrated into the joint space rapidly, with maximal concentrations of 6.6 microM reached at approximately 1 h postdose. The unbound MTX area under the curve in SF was approximately 40% of the total area under the curve in plasma. These data agree well with the previous data obtained for MTX using arthrocentesis.

Conclusion: In contrast with arthrocentesis, microdialysis enables the collection of multiple serial SF samples from individual animals with minimal trauma and potential blood contamination. This animal model should prove valuable for studying the disposition of new antiarthritis compounds or biomarkers in SF.

Citing Articles

Novel in vitro dynamic metabolic system for predicting the human pharmacokinetics of tolbutamide.

Xue C, Zhang Z, Jin Y, Zhu B, Xing J, Ma G Acta Pharmacol Sin. 2018; 39(9):1522-1532.

PMID: 29644999 PMC: 6289352. DOI: 10.1038/aps.2017.201.

Population pharmacokinetic analysis of blood and joint synovial fluid concentrations of robenacoxib from healthy dogs and dogs with osteoarthritis.

Silber H, Burgener C, Letellier I, Peyrou M, Jung M, King J Pharm Res. 2010; 27(12):2633-45.

PMID: 20922466 DOI: 10.1007/s11095-010-0262-z.

AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives.

Chaurasia C, Muller M, Bashaw E, Benfeldt E, Bolinder J, Bullock R Pharm Res. 2007; 24(5):1014-25.

PMID: 17458685 DOI: 10.1007/s11095-006-9206-z.

References

Lu G, Jun H, Dzimianski M, Qiu H, McCall J . Pharmacokinetic studies of methotrexate in plasma and synovial fluid following i.v. bolus and topical routes of administration in dogs. Pharm Res. 1995; 12(10):1474-7. DOI: 10.1023/a:1016231303689. View

Day R, McLachlan A, Graham G, Williams K . Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid. Clin Pharmacokinet. 1999; 36(3):191-210. DOI: 10.2165/00003088-199936030-00002. View

Benveniste H, Huttemeier P . Microdialysis--theory and application. Prog Neurobiol. 1990; 35(3):195-215. DOI: 10.1016/0301-0082(90)90027-e. View

Chu J, Gallo J . Application of microdialysis to characterize drug disposition in tumors. Adv Drug Deliv Rev. 2000; 45(2-3):243-53. DOI: 10.1016/s0169-409x(00)00115-0. View

Menacherry S, HUBERT W, Justice Jr J . In vivo calibration of microdialysis probes for exogenous compounds. Anal Chem. 1992; 64(6):577-83. DOI: 10.1021/ac00030a003. View

Wu J, Zeng H, Qian M, Brogdon B, Unger S . Direct plasma sample injection in multiple-component LC-MS-MS assays for high-throughput pharmacokinetic screening. Anal Chem. 2000; 72(1):61-7. DOI: 10.1021/ac990769y. View

Elmquist W, Chan K, Sawchuk R . Transsynovial drug distribution: synovial mean transit time of diclofenac and other nonsteroidal antiinflammatory drugs. Pharm Res. 1994; 11(12):1689-97. DOI: 10.1023/a:1018994712387. View

Rittenhouse K, Pollack G . Microdialysis and drug delivery to the eye. Adv Drug Deliv Rev. 2000; 45(2-3):229-41. DOI: 10.1016/s0169-409x(00)00112-5. View

Maia M, Saivin S, Chatelut E, Malmary M, Houin G . In vitro and in vivo protein binding of methotrexate assessed by microdialysis. Int J Clin Pharmacol Ther. 1996; 34(8):335-41. View

10.

Herrera A, Scott D, Lunte C . Microdialysis sampling for determination of plasma protein binding of drugs. Pharm Res. 1990; 7(10):1077-81. DOI: 10.1023/a:1015955503708. View

11.

Wang Y, Wong S, Sawchuk R . Microdialysis calibration using retrodialysis and zero-net flux: application to a study of the distribution of zidovudine to rabbit cerebrospinal fluid and thalamus. Pharm Res. 1993; 10(10):1411-9. DOI: 10.1023/a:1018906821725. View

12.

Wallis W, Simkin P . Antirheumatic drug concentrations in human synovial fluid and synovial tissue. Observations on extravascular pharmacokinetics. Clin Pharmacokinet. 1983; 8(6):496-522. DOI: 10.2165/00003088-198308060-00002. View

13.

Stahle L . On mathematical models of microdialysis: geometry, steady-state models, recovery and probe radius. Adv Drug Deliv Rev. 2000; 45(2-3):149-67. DOI: 10.1016/s0169-409x(00)00108-3. View

14.

Davies M, Lunte C . Microdialysis sampling for hepatic metabolism studies. Impact of microdialysis probe design and implantation technique on liver tissue. Drug Metab Dispos. 1995; 23(10):1072-9. View